贝伐珠单抗与乳腺癌：当前的治疗进展和未来展望。
Bevacizumab and breast cancer: current therapeutic progress and future perspectives.
机构信息
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Building, 37/Room 1048, 37 Convent Drive, Bethesda, MD 20892 USA.
出版信息
Expert Rev Anticancer Ther. 2009 Dec;9(12):1715-25. doi: 10.1586/era.09.153.
Abstract
Bevacizumab is a humanized monoclonal antibody to VEGF, and the incorporation of bevacizumab to chemotherapy is one of the rapidly evolving areas in the treatment of breast cancer. Bevacizumab in combination with chemotherapy versus chemotherapy alone improves progression-free survival and increases the response rate in first-line therapy for locally recurrent or metastatic breast cancer. This approach has been and is still being evaluated for early breast cancer in neoadjuvant and adjuvant settings. Bevacizumab is well tolerated and has an established tolerability profile. Both tumor- and host-related biomarkers of bevacizumab activity, response and benefit are emerging from Phase I, II and III clinical trials. The biomarkers of benefit will ultimately help identify the subgroups of patients who specifically benefit from anti-VEGF therapy with bevacizumab.
摘要
贝伐珠单抗是人源化抗血管内皮生长因子（VEGF）单克隆抗体，贝伐珠单抗联合化疗是乳腺癌治疗中迅速发展的领域之一。贝伐珠单抗联合化疗对比单纯化疗，可改善局部复发或转移性乳腺癌患者的无进展生存期并提高缓解率。该方案已在局部复发或转移性乳腺癌的新辅助和辅助治疗中进行了评估，且仍在评估早期乳腺癌患者的应用。贝伐珠单抗耐受性良好，具有明确的可耐受特征。贝伐珠单抗的活性、疗效和获益的肿瘤相关和宿主相关生物标志物，正不断从 I 期、II 期和 III 期临床试验中涌现。获益的生物标志物最终将有助于确定哪些亚组患者可特异性地从贝伐珠单抗的抗血管内皮生长因子治疗中获益。
相似文献
1
Bevacizumab and breast cancer: current therapeutic progress and future perspectives.贝伐珠单抗与乳腺癌：当前的治疗进展和未来展望。
Expert Rev Anticancer Ther. 2009 Dec;9(12):1715-25. doi: 10.1586/era.09.153.
2
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.针对内分泌难治性或耐药性转移性乳腺癌的血管内皮生长因子（VEGF）靶向治疗。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008941. doi: 10.1002/14651858.CD008941.pub2.
3
Bevacizumab in the treatment of breast cancer.贝伐珠单抗治疗乳腺癌。
Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22.
4
Bevacizumab in the treatment of breast cancer: rationale and current data.贝伐单抗治疗乳腺癌：理论依据与当前数据。
Oncologist. 2004;9 Suppl 1:43-9. doi: 10.1634/theoncologist.9-suppl_1-43.
5
Vascular endothelial growth factor and bevacitumab in breast cancer.血管内皮生长因子与贝伐单抗在乳腺癌中的应用
Breast Cancer. 2007;14(2):163-73. doi: 10.2325/jbcs.968.
6
Bevacizumab for advanced breast cancer.贝伐单抗用于晚期乳腺癌。
Hematol Oncol Clin North Am. 2007 Apr;21(2):303-19. doi: 10.1016/j.hoc.2007.03.006.
7
The role of angiogenesis inhibition in the treatment of breast cancer.血管生成抑制在乳腺癌治疗中的作用。
Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2.
8
Angiogenesis inhibition in the treatment of lung cancer.血管生成抑制在肺癌治疗中的应用
Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2.
9
[Anti-VEGF therapy with bevacizumab in breast cancer].[贝伐单抗用于乳腺癌的抗血管内皮生长因子治疗]
Lege Artis Med. 2008 Oct;18(10):669-73.
10
Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.研究贝伐单抗在其他适应症中的潜力：转移性肾细胞癌、非小细胞肺癌、胰腺癌和乳腺癌。
Oncology. 2005;69 Suppl 3:46-56. doi: 10.1159/000088483. Epub 2005 Nov 21.
引用本文的文献
1
Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.从更广泛视角理解休眠乳腺癌细胞的“捉迷藏”策略及其在肿瘤学中的意义的进展：全面概述
Curr Issues Mol Biol. 2024 Aug 1;46(8):8340-8367. doi: 10.3390/cimb46080492.
2
Leukocytes as carriers for targeted cancer drug delivery.白细胞作为靶向癌症药物递送的载体。
Expert Opin Drug Deliv. 2015 Mar;12(3):375-92. doi: 10.1517/17425247.2015.966684. Epub 2014 Oct 1.
3
Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.小激活RNA恢复肿瘤抑制因子HIC-1对乳腺癌的活性。
PLoS One. 2014 Jan 28;9(1):e86486. doi: 10.1371/journal.pone.0086486. eCollection 2014.
4
Radiotherapy in combination with vascular-targeted therapies.放疗联合血管靶向治疗。
Radiol Oncol. 2010 Jun;44(2):67-78. doi: 10.2478/v10019-010-0025-9. Epub 2010 May 24.
5
Bevacizumab and breast cancer: what does the future hold?贝伐珠单抗与乳腺癌：未来如何？
Future Oncol. 2012 Apr;8(4):403-14. doi: 10.2217/fon.12.22.
6
Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.血清 sTRAIL 水平升高与贝伐珠单抗治疗转移性结直肠癌的生存相关。
BMC Cancer. 2012 Feb 7;12:58. doi: 10.1186/1471-2407-12-58.
7
Characteristics of human Ewing/PNET sarcoma models.人类尤因肉瘤/原始神经外胚层肿瘤（Ewing/PNET）模型的特征。
Ann Saudi Med. 2011 Mar-Apr;31(2):174-82. doi: 10.4103/0256-4947.78206.
8
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.p53、HER2 与肿瘤细胞凋亡与乳腺癌新辅助贝伐珠单抗联合化疗后的临床结局相关。
Int J Oncol. 2011 May;38(5):1445-52. doi: 10.3892/ijo.2011.966. Epub 2011 Mar 9.
9
¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.¹⁸F-FDG PET 与早期乳腺癌肿瘤血管生成的生物标志物。
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):46-52. doi: 10.1007/s00259-010-1590-2. Epub 2010 Aug 14.
本文引用的文献
1
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.RIBBON-1：一项针对人表皮生长因子受体 2 阴性、局部复发性或转移性乳腺癌一线治疗的化疗联合或不联合贝伐珠单抗的随机、双盲、安慰剂对照 III 期临床试验。
J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.
2
Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells.
Oncology. 2009;77(3-4):182-91. doi: 10.1159/000236016. Epub 2009 Sep 3.
3
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.E2100的独立评估：一项贝伐单抗联合紫杉醇对比紫杉醇治疗转移性乳腺癌女性患者的III期试验
J Clin Oncol. 2009 Oct 20;27(30):4966-72. doi: 10.1200/JCO.2008.21.6630. Epub 2009 Aug 31.
4
Biomarkers of response and resistance to antiangiogenic therapy.抗血管生成治疗反应和耐药性的生物标志物。
Nat Rev Clin Oncol. 2009 Jun;6(6):327-38. doi: 10.1038/nrclinonc.2009.63.
5
Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.骨髓来源的内皮祖细胞有助于肿瘤生长和转移进展中的血管生成转换。
Biochim Biophys Acta. 2009 Aug;1796(1):33-40. doi: 10.1016/j.bbcan.2009.05.001. Epub 2009 May 19.
6
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.术前多西他赛联合或不联合贝伐单抗用于局部晚期乳腺癌的血管靶向治疗方案：对血管生成生物标志物的影响
Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5.
7
A compact VEGF signature associated with distant metastases and poor outcomes.一种与远处转移和不良预后相关的紧密型血管内皮生长因子特征。
BMC Med. 2009 Mar 16;7:9. doi: 10.1186/1741-7015-7-9.
8
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.新辅助贝伐单抗、多西他赛和卡培他滨联合治疗HER2/neu阴性浸润性乳腺癌：一项II期初步研究的疗效与安全性
Eur J Surg Oncol. 2009 Oct;35(10):1048-54. doi: 10.1016/j.ejso.2009.01.014. Epub 2009 Feb 27.
9
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.参与血管生成与淋巴管生成的血管内皮生长因子及其受体。
Curr Opin Cell Biol. 2009 Apr;21(2):154-65. doi: 10.1016/j.ceb.2008.12.012. Epub 2009 Feb 21.
10
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.对于具有不良预后特征的局部晚期乳腺癌患者，采用氟尿嘧啶、表柔比星和顺铂持续静脉滴注，随后每周给予紫杉醇加贝伐单抗治疗。
Anticancer Drugs. 2009 Mar;20(3):197-203. doi: 10.1097/CAD.0b013e3283264719.
Zotero 插件